- Home
- NTIP vs DYAI Comparison
NTIP vs DYAI Comparison
Compare NTIP & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- DYAI
- Stock Information
- Founded
- NTIP 1990
- DYAI 1979
- Country
- NTIP United States
- DYAI United States
- Employees
- NTIP N/A
- DYAI N/A
- Industry
- NTIP Multi-Sector Companies
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NTIP Miscellaneous
- DYAI Health Care
- Exchange
- NTIP Nasdaq
- DYAI Nasdaq
- Market Cap
- NTIP 32.0M
- DYAI 28.3M
- IPO Year
- NTIP 1998
- DYAI 2004
- Fundamental
- Price
- NTIP $1.42
- DYAI $1.15
- Analyst Decision
- NTIP
- DYAI Strong Buy
- Analyst Count
- NTIP 0
- DYAI 1
- Target Price
- NTIP N/A
- DYAI $6.00
- AVG Volume (30 Days)
- NTIP 36.9K
- DYAI 199.4K
- Earning Date
- NTIP 08-11-2025
- DYAI 08-12-2025
- Dividend Yield
- NTIP 7.04%
- DYAI N/A
- EPS Growth
- NTIP N/A
- DYAI N/A
- EPS
- NTIP N/A
- DYAI N/A
- Revenue
- NTIP $250,000.00
- DYAI $3,554,344.00
- Revenue This Year
- NTIP N/A
- DYAI $22.56
- Revenue Next Year
- NTIP N/A
- DYAI $30.95
- P/E Ratio
- NTIP N/A
- DYAI N/A
- Revenue Growth
- NTIP N/A
- DYAI 57.59
- 52 Week Low
- NTIP $1.16
- DYAI $0.91
- 52 Week High
- NTIP $1.78
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- NTIP 62.66
- DYAI 71.14
- Support Level
- NTIP $1.40
- DYAI $0.98
- Resistance Level
- NTIP $1.46
- DYAI $1.20
- Average True Range (ATR)
- NTIP 0.06
- DYAI 0.09
- MACD
- NTIP 0.01
- DYAI 0.02
- Stochastic Oscillator
- NTIP 80.43
- DYAI 65.28
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.